In another study, it was also confirmed that FGL2 activates this pathway and the NLRP3 inflammasome aggravated nonalcoholic steatohepatitis (NASH) and promoted lipid metabolism disorders 69. Here, FGL2 is linked to metabolic dysfunction-associated steatohepatitis.